🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-520627-25-00
Authorised Phase IV

A single centre parallel-group randomized control trial of Magnetic Resonance Assessment of Variations in Effects of anaesthesia on renaL perfusion in children

2025-520627-25-00 · tracked via the Priya Life Science EU tracker
Sponsor
Region Uppsala
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Physiological processes
Decision date
26/09/2025
Enrollment target
50
Sites
Sweden

Condition studied

Post-operative Acute Kidney Injury

Investigational medicinal product(s)

PROPOFOLSEVOFLURANE

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Differences in RBF, as measured by phase contrast imaging with mpMRI, between propofol and sevoflurane anesthesia.

Endpoint detail

The difference plasma renin concentration, measured by a blood sample, between propofol and sevoflurane anaesthesia, The difference in relation of RBF to systemic non-invasive blood pressure, between propofol and sevoflurane anaesthesia, Differences in regional and global renal oxygenation, as measured by Blood Oxygen Level Dependent (BOLD) signal via mpMRI, between propofol and sevoflurane anaesthesia., Differences in regional renal tissue perfusion, as measured by arterial spin labelling (ASL) with mpMRI, between propofol and sevoflurane anaesthesia

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-520627-25-00 on CTIS ↗ ← All trials in the EU